ReviewStructural heart : the journal of the Heart Team2025
The Staging of Cardiac Damage for Aortic Stenosis: A Review.
Review in Structural heart : the journal of the Heart Team, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Trajectories of cardiac damage staging after transcatheter aortic valve replacement and long-term outcomes.Cardiovascular intervention and therapeutics · 2026Article
- Article
- Staged Therapeutic Approach to Concomitant Severe Aortic Stenosis and Atrial Septal Defect: Addressing Dual Mechanisms of Heart Failure-Case Report and Literature Review.Life (Basel, Switzerland) · 2026Article
- The Cost of Delayed Transcatheter Aortic Valve Replacement.Structural heart : the journal of the Heart Team · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent and success of transcatheter aortic valve replacement (TAVR) for the treatment of severe, symptomatic aortic stenosis (AS) has sparked a renewed interest in the disease process associated with the valve disorder. While it is evident that untreated AS is fatal, the progressive and cumulative effects of AS on the heart have only recently been studied in a widespread fashion, after the initial pivotal TAVR trials in the United States. From these data, a novel staging system has been developed to characterize the extent of cardiac damage caused by AS. This staging system facilitates risk stratification of patients with AS using echocardiographic data and measurements to derive an assessment of morbidity and mortality. After being successfully validated using outcomes from several TAVR trials, the model has now been extrapolated to patients with moderate AS and other cardiac valve disorders as well. In this review, we explore the origins of the cardiac damage staging system, its validation, and uses in various cardiac conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.